Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Kyowa Kirin Set to Gain Tens of Billions of Yen in Sales from Orchard Acquisition
Kyowa Kirin said on October 19 that it expects to generate revenues in the ballpark of tens of billions of yen from the three products that it will take over through the purchase of UK-based Orchard Therapeutics. It also foresees…
To read the full story
Related Article
- FDA Clears Orchard’s Lenmeldy Gene Therapy for MLD
March 22, 2024
- Kyowa Kirin Closes Acquisition of UK Gene Therapy Player Orchard
January 25, 2024
- Kyowa Kirin to Acquire Orchard to Forge Ahead in Gene Therapy
October 6, 2023
BUSINESS
- Ultragenyx Seeks Japan Approval for GSDIa Gene Therapy
July 1, 2026
- Asahi Kasei Nabs Japan Rights to Additional Empaveli Indications
July 1, 2026
- Viatris Eyes Japan Filing This Year for IgAN Drug
July 1, 2026
- Expert Calls for Greater Awareness of LC-FAOD after Dojolvi Debut
June 30, 2026
- Toho Defense Measure Scraped through Shareholder Vote: Report
June 30, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…